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Abstract
Background: Vinclozolin is a fungicide that has been reported to have anti-androgenic effects in rats. We have
found that in utero exposure to natural or synthetic progesterones can induce hypospadias in mice, and that the
synthetic progesterone medroxyprogesterone acetate (MPA) feminizes male and virilizes female genital tubercles.
In the current work, we selected a relatively low dose of vinclozolin to examine its in utero effects on the
development of the genital tubercle, both at the morphological and molecular levels.
Methods: We gave pregnant dams vinclozolin by oral gavage from gestational days 13 through 17. We assessed
the fetal genital tubercles from exposed fetuses at E19 to determine location of the urethral opening. After
determination of gonadal sex, either genital tubercles were harvested for mRNA quantitation, or urethras were
injected with a plastic resin for casting. We analyzed quantified mRNA levels between treated and untreated
animals for mRNA levels of estrogen receptors α and β, progesterone receptor, and androgen receptor using
nonparametric tests or ANOVA. To determine effects on urethral length (males have long urethras compared to
females), we measured the lengths of the casts and performed ANOVA analysis on these data.
Results: Our morphological results indicated that vinclozolin has morphological effects similar to those of MPA,
feminizing males (hypospadias) and masculinizing females (longer urethras). Because these results reflected our
MPA results, we investigated the effects of in utero vinclozolin exposure on the mRNA expression levels of
androgen, estrogen α and β, and progesterone receptors. At the molecular level, vinclozolin down-regulated
estrogen receptor α mRNA in females and up-regulated progesterone receptor mRNA. Vinclozolin-exposed
males exhibited up-regulated estrogen receptor α and progesterone receptor mRNA, effects we have also seen
with exposure to the synthetic estrogen, ethinyl estradiol.
Conclusion: The results suggest that vinclozolin virilizes females and directly or indirectly affects progesterone
receptor expression. It also affects estrogen receptor expression in a sex-based manner. We found no in vivo
effect of vinclozolin on androgen receptor expression. We propose that vinclozolin, which has been designated
an anti-androgen, may also exert its effects by involving additional steroid-signaling pathways.
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Introduction
Vinclozolin has been identified as an anti-androgenic
endocrine disruptor that produces malformations related
to androgen inhibition in rats [1]. This fungicide, used on
food crops (soft fruits and vegetables) such as grapes used
in wine [2], can be toxic in high doses, but its "no
observed adverse effects level" is considered to be between
1 and 3 mg/kg in rats [3].
Vinclozolin is known to affect androgen-receptor-medi-
ated endpoints [1,4-8], but some research on behaviors
inferred to be androgen-mediated indicates that proges-
terone receptors may also be involved in the manifesta-
tion of these behaviors since mice lacking the
progesterone receptor exhibit alterations or decreases in
these ostensibly androgen-mediated behaviors [9,10].
Vinclozolin has been shown to affect androgen-receptor-
mediated behaviors in mammals [11] and birds [12]. In
addition, research indicates an inability for vinclozolin to
compete for androgen receptor in the fathead minnow
[13], even though it disrupts male steroid profiles and
alters female gonadal condition in adults [13]. Although
most of these studies are behavioral, they do imply the
involvement of steroid receptors other than androgen
receptors in these processes.
In a study with rats, androgen receptor mRNA was unaf-
fected by vinclozolin exposure [5]. Laws et al. [14] found
that the two anti-androgenic metabolites of vinclozolin
can compete with progesterone for progesterone receptor
in vitro, but do not bind estrogen receptor. Their in vivo
studies, however, indicated that vinclozolin did not dis-
rupt progesterone-receptor-based pathways in adult ani-
mals; for example, it elicited no change in ovulation in
adult female rats, and the researchers found no changes in
progesterone receptor distribution after short-term vin-
clozolin exposure.
The study by Laws et al. [14] was performed using adult
rats. Part of the endocrine-disruptor model is the choice of
sensitive developmental time-points at which the organ-
ism may be most susceptible to exposure, especially to
low-dose exposure (Crews et al. 2000). We investigated
how a relatively low dose of vinclozolin affected fetal gen-
ital tubercle development in mice, a steroid-dependent
process. Our results led us to conduct further investiga-
tions into the effects of in utero vinclozolin exposure on
steroid receptor expression in the genital tubercle, espe-
cially progesterone receptor.
Materials and methods
Casting
Timed-pregnant CD1 mice were received on gestational
day 8 (Charles River Laboratories, Wilmington, MA, USA)
and housed in separate animal cages until embryonic
stage (E) 13. All animals were housed one per cage (20 ×
25 × 47 cm) with laboratory-grade pine shavings (heat-
treated to remove resins) as bedding. They were accli-
mated to 68–74°F and 40%–50% relative humidity on a
reversed light schedule (14 hr light and 10 hr dark) and
received ad libitum mouse chow and water. All animal-
related procedures described here were approved by our
institutional animal care and use committee.
The pregnant mice were separated into three groups (N >
6 each); vehicle control (corn oil only), a low dose of vin-
clozolin (D1 = 10 mg/kg dissolved in corn oil), and a
higher dose of vinclozolin (D2 = 50 mg/kg dissolved in
corn oil). On gestational day (GD) 13 (the start of genital
tubercle differentiation), we began daily gavaging of the
pregnant mice with 0.1 ml of either corn oil (control), D1
vinclozolin, or D2 vinclozolin. Gavaging ended on gesta-
tional day 17. On GD 19, dams were killed by CO2 fol-
lowed by cervical dislocation, and the fetuses were
harvested via cesarean section and sex was determined by
microscopic examination of gonads.
For casting, each fetal bladder/urethra was cast by injec-
tion (Baston's No. 17 Plastic Replica and Corrosion Kit
(Polysciences, Inc., Warrington, PA, USA) using a 30
gauge needle with 3× microscopic visualization. The cast-
ing material was injected into the bladder until it emerged
from the urethral opening. Casts set overnight at 4°C and
were transferred to 20% potassium hydroxide the follow-
ing day to dissolve the remaining tissue. The fetal bladder/
urethra casts were photographed using a digital camera
Table 1: Summary of experimental conditions for quantitative PCR
Pup gender # E19 GTs examined # pools obtained # pools omitted # samples/pool
Control N = 8 (dams) Females 46 6 0 7–8
Males w/hypos 0 - - -
Males w/o 48 10 0 4–5
Vinc-treated N = 12 (dams) Females 49 7 0 7
Males w/hypos 8 3 0 2–3
Males w/o 51 6 0 8–9
GT = genital tubercle; hypos = hypospadias.Environmental Health: A Global Access Science Source 2006, 5:4 http://www.ehjournal.net/content/5/1/4
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(Nikon 900, Melville, NY, USA). Using Adobe Photoshop
7.0 (Apple, Sunnyvale), we obtained fetal urethral meas-
urements of urethral length based on pixel count. In the
male pups, additional measurements were made from the
prostate gland to Cowper's gland and from Cowper's
gland to the distal urethral tip.
RT-PCR and macroscopic assessment of hypospadias
Timed pregnant CD1 mice (Charles River Breeding Labo-
ratories, Wilmington, MA) were received on GD 8. Mice
were gavaged once daily from GD 13 through 17 with 50
mg/kg vinclozolin or with corn oil alone as the vehicle
control. We selected the dose of vinclozolin based on
results published by Grey et al.4 showing that this was the
lowest dose that elicited frank hypospadias in male rats
exposed in utero; our goal for this set of experiments was
to elicit hypospadias for molecular studies of the pathway.
We also selected it based on preliminary investigations of
our own indicating that this dose would produce hypos-
padias at a frequency that would allow us to compare tis-
sue from hypospadic and nonhypospadic animals at the
molecular level. All animals were housed as described
above. Fetal genital tubercle morphology was assessed
and tissue harvested on GD 19 (when urethral closure at
the tip of genital tubercle normally has occurred) [16].
Dams were killed by CO2 followed by cervical dislocation
and fetuses removed. After gross examination and identi-
fication of the location of the urethral opening (either low
or normal), gonadal sex was identified, and genital tuber-
cles were harvested by microdissection and placed in
RNAlater (Qiagen) for RNA isolation for RT-PCR analysis.
Visual assessment of urethra
Gross assessment of the location of the urethral opening
was made primarily by expressing the bladder and observ-
ing the emergence of fluid; in normal E19 males, it
emerges at the tip of the genital tubercle; in hypospadias
it emerges more proximally.
Quantitative RT-PCR analysis
Total RNA from pooled tissues was extracted using a kit
(Qiagen). It was reverse-transcribed to cDNA and quanti-
tative RT-PCR analysis using the Taqman assay was per-
formed at UCSF's Cancer Center Comprehensive Genome
Analysis Core. Primers for the steroid receptors (the two
estrogen receptors, progesterone receptor, and androgen
receptor) were obtained commercially (Applied Biosys-
tems, Foster City, CA). The gene expression assay used for
progesterone receptor (Mm00435625) did not distin-
guish between the two isoforms; thus, quantification
reflects expression of both PR-A and PR-B. Table 1 pro-
vides numbers of dams and pups and number of individ-
uals per pooled sample of tissue analyzed. Data for
receptor mRNA levels were normalized to the control
gene, GapDH. This gene was chosen because it was shown
to be the least variable under these experimental condi-
tions (data not shown).
Length of female urethral casts Figure 1
Length of female urethral casts. Female urethras were 
significantly longer in the fetuses from the higher-dose (D2, 
50 mg/kg) vinclozolin group. * = P < 0.05 vs. control. A 
longer urethra indicates virilization of the female. D1 = 10 
mg/kg. Ctrl = mice born to dams gavaged with corn oil only.
Male urethras and hypospadias Figure 2
Male urethras and hypospadias. Top row shows control 
(A, left) and treated (B, right, higher-dose group) macro-
scopic view of male fetal genital tubercle. Note the normal 
location of the urethral opening (arrow, left) and the more-
proximal opening the in treated sample (arrow, right), indi-
cating hypospadias. Urethral openings were visualized by 
emergence of casting resin from the opening. The bottom 
row shows a typical control male cast (C, left) and a male 
urethral cast from the higher-dose group (D, right). Note the 
lack of an "S" shape and the overall atrophic appearance of 
the urethra from the treated male (right).Environmental Health: A Global Access Science Source 2006, 5:4 http://www.ehjournal.net/content/5/1/4
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Statistical analyses
Statistical analyses were performed using JMP for PC. We
used ANOVA analysis on the urethral cast length measure-
ments. RT-PCR data, when not normally distributed, were
analyzed and are reported based on a nonparametric
median test; we also performed Grubb's outlier tests on
RT-PCR data. For normally distributed RT-PCR data, we
used ANOVA analysis.
Results
Urethral casting
Urethras from female E19 fetuses exposed to the higher
dose of vinclozolin were significantly longer than the con-
trol female urethras (P = 0.005) (Fig. 1). In addition, the
urethral lengths appeared to exhibit a dose response, with
the female urethras from the lower-dose group exhibiting
lengths intermediate to the control and higher-dose
groups (Fig. 1). Urethras from female exposed to the
lower dose of vinclozolin were not significantly longer
than those from controls (P = 0.08).
The statistical analysis did not show any differences in
urethral length among the males in the groups; however,
visually, the urethras from vinclozolin-exposed males
appeared considerably less robust and atrophic, and lack-
ing in the typical "S" shape of a control urethra (Fig. 2).
RT-PCR results
Of the male genital tubercles examined macroscopically,
we identified 8 of 59 (13.6%) as having hypospadias.
None of the control male genital tubercles were identified
as having hypospadias.
Progesterone receptor
Vinclozolin-treated males had higher levels of progester-
one receptor mRNA than control males (ANOVA, df = 1;
F ratio = 14.1; P = 0.0016) (Fig. 3). In addition, vinclozo-
lin-treated females had significantly higher levels of pro-
gesterone receptor mRNA in the genital tubercle (ANOVA,
df = 1; F ratio = 52.07; P < 0.0001) (Fig. 3).
When we separated vinclozolin-treated males into two
groups, those with and those without hypospadias, we
found significant differences between each group com-
pared to controls (P = 0.004 and P = 0.02, respectively)
(not shown).
Control males and females did not differ in progesterone
receptor mRNA expression (not shown).
Estrogen receptors
Estrogen receptor α was significantly lower in vinclozolin-
treated females (ANOVA, df = 1; F ratio = 58.86; P <
0.0001) (Fig. 4). In addition, vinclozolin-treated females
exhibited lower levels of estrogen receptor β compared to
Estrogen receptor α mRNA expression in females and males  compared between control and treated groups Figure 4
Estrogen receptor α mRNA expression in females 
and males compared between control and treated 
groups. In vinclozolin-treated females, mRNA expression 
was significantly lower compared to controls. In treated 
males, mRNA expression was significantly higher compared 
to controls. *, P < 0.05 compared to same-sex controls. 
Males, females = mice born to dams gavaged with corn oil 
only. TxdM = treated males; TxdF = treated females. Treated 
animals were born to females gavaged with 50/mg/kg vincloz-
olin daily from E13 through E17.
Progesterone receptor mRNA expression in females and  males compared between control and treated groups Figure 3
Progesterone receptor mRNA expression in females 
and males compared between control and treated 
groups. In both sexes, progesterone receptor levels were 
significantly higher in genital tubercles from treated animals 
compared to those from control animals. *, P < 0.05 com-
pared to same-sex controls. Males, females = mice born to 
dams gavaged with corn oil only. TxdM = treated males; 
TxdF = treated females. Treated animals were born to 
females gavaged with 50/mg/kg vinclozolin daily from E13 
through E17.Environmental Health: A Global Access Science Source 2006, 5:4 http://www.ehjournal.net/content/5/1/4
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controls (ANOVA, df = 1; F ratio = 7.62; P = 0.019) (not
shown).
We found one outlier among the control males group
(Grubb's outlier test) and removed it from the analysis.
Estrogen receptor expression α was slightly significantly
higher in vinclozolin-treated males than in control males
(Wilcoxon's, df = 1; P = 0.03) (Fig. 4).
Androgen receptor
We found no significant changes in androgen receptor in
comparisons among the groups.
Discussion
Recent research suggests that compounds we believed
were estrogenic may really be disrupting endocrine signal-
ing via the progesterone receptor [17]. Recently some pro-
gesterone disruptors have been identified in personal care
products [18]. In utero exposure to natural or synthetic
progesterones can induce hypospadias in mice in which
the urethral opening occurs more proximally than nor-
mal; the synthetic progesterone medroxyprogesterone
acetate (MPA) feminizes male and virilizes female genital
tubercles (EW et al. in preparation). In the current work,
the relatively low dose of vinclozolin used caused hypos-
padias in the mice, but it also virilized the females, reflect-
ing our findings with MPA. We also have observed a more
proximal urethral opening in females treated with natural
progesterone, but have not quantified these data (unpub-
lished data).
Our morphological findings with vinclozolin, in the con-
text of our findings with MPA and progesterone, led us to
investigate the effects of vinclozolin on progesterone
receptor expression, and on the expression of other ster-
oid hormone receptors. In a study with rats, an in vitro
assessment of the ability of two vinclozolin metabolites to
bind progesterone receptor indicated that it could out-
compete the natural ligand; however, the concordant in
vivo studies from these investigations using adult male rats
showed no in vivo effect [14]. The discrepancy between
these data and our current results could be attributable to
species differences or differential responses based on tim-
ing of exposure. Our mice experienced vinclozolin expo-
sure  in utero, rather than as adults, and a central
assumption of the endocrine-disruption model is that in
utero exposures exert different and more powerful effects
than do exposures in adults [15]. In addition, our results
are consistent between the morphological and molecular
levels in males.
Vinclozolin-exposed males exhibited up-regulated estro-
gen receptor α and up-regulated progesterone receptor,
effects we have also seen with exposure to the synthetic
estrogen, ethinyl estradiol (unpublished data). Ethinyl
estradiol up-regulates estrogen receptor α in females and
upregulates progesterone receptor in both sexes. MPA also
up-regulates estrogen receptor α and progesterone recep-
tor in males, which it feminizes.
Vinclozolin can cause an increase in aromatase activity
[19], which would presumably result in an increase in
estradiol, especially in a system where testosterone is
being made in abundance, as is the case with the male dif-
ferentiation pathway. In fact, in the fathead minnow, a
species that serves as a model of vertebrate endocrine dis-
ruption, vinclozolin exposure resulted in a slight increase
in estradiol concentrations in adult male fish [13]. Thus,
vinclozolin could act on aromatase, which in turn could
act on testosterone, both producing estradiol inappropri-
ately and depriving 5-alpha-reductase of the substrate it
needs to produce dihydrotesterone, the androgen neces-
sary for appropriate male development of secondary sex
characteristics. One possible explanation for the up-regu-
lation of progesterone receptor mRNA in males could be
the boosted estrogen receptor expression; estrogen recep-
tor binds the progesterone receptor promoter. But another
potential explanation, given the fact that vinclozolin
binds progesterone receptor in vitro, is that it is affecting
the receptor directly.
At the molecular level, vinclozolin down-regulated
expression of estrogen receptors α and β in females and
up-regulated progesterone receptor expression. Intui-
tively, the results with estrogen receptor suggest a lessen-
ing effect of estrogen, which would be consistent with our
findings of virilization in the females. Androgen receptor
expression remained unchanged in females. We speculate
that the virilization that occurred in the female genital
tubercle may have been the result of indirect estrogen
antagonism; vinclozolin does not appear to be an estro-
gen receptor agonist or antagonist [20]. It may enhance
aromatase activity, and the up-regulation in aromatase
activity may exhaust available substrate with the ultimate
effect of lessening available estrogen. In addition, if sign-
aling through the progesterone receptor is involved in the
development of endpoints that are thought to be andro-
gen-mediated, the increase in progesterone receptor in
females may provide more opportunity for the develop-
ment of these ostensibly androgen-associated pheno-
types.
Conclusion
Our findings suggest that vinclozolin directly or indirectly
affects progesterone receptor expression and that it also
affects estrogen receptor expression in a sex-based man-
ner. We found no in vivo effect of vinclozolin on androgen
receptor expression in this tissue. We propose that vin-
clozolin, long designated as an anti-androgen, may alsoPublish with BioMed Central    and   every 
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exert its effects by additional steroid-hormone signaling
pathways.
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